Long-Term Antidepressant Efficacy and Safety of Olanzapine/Fluoxetine Combination: A 76-Week Open-Label Study

Journal of Clinical Psychiatry

Volumn 64, Issue 11, 2003, Pages 1349-1356

  Corya, Sara A ^a   Andersen, Scott W ^c   Detke, Holland C ^a   Kelly, Linda S ^c   Van Campen, Luann E ^a   Sanger, Todd M ^a   Williamson, Douglas J ^a   Dubé, Sanjay ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Lilly Corporate Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BILIRUBIN; CHOLESTEROL; FLUOXETINE; GLUCOSE; LORAZEPAM; OLANZAPINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; INSOMNIA; LABORATORY TEST; LIBIDO DISORDER; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OPEN STUDY; PAIN; PARKINSONISM; PHARYNGITIS; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RATING SCALE; RELAPSE; REMISSION; RHINITIS; SCORING SYSTEM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0344551192     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n1111     Document Type: Article

References (46)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996;19:371-386
3. Fawcett J. Progress in treatment-resistant depression and treatment-refractory depression: we still have a long way to go. Psychiatr Ann 1994;24:214-216
4. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51 (suppl 6):39-47;discussion 48-50
5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
6. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91
7. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58:23-29
8. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
9. Tohen M, Vieta E, Ketter T, et al. Olanzapine in the treatment of bipolar depression [abstract]. Int J Neuropsychopharmacol 2002:5(suppl 1):S109
10. Williamson DJ, Andersen SW, Van Campen LE, et al. A double-blind study of olanzapine/fluoxetine combination for treatment of psychotic major depression [abstract]. Biol Psychiatry 2001;49(suppl 8S):104S
11. IMS Health. National Disease and Therapeutic Index; 2002
12. First MB, Spitzer, RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1996
13. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview for DSM-III-R, Patient Edition/Non-Patient Edition (SCID-P/SCID-NP). Washington, DC: American Psychiatric Press; 1990
14. National Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21:714-1124
15. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
16. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;(suppl 212):11-19
17. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
18. Munetz MR, Benjamin S. How to evaluate patients using the abnormal involuntary movement scale. Hosp Community Psychiatry 1988;39:1172-1177
19. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
20. Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF. Drug Inf J 2001;35:1215-1225
21. Dmitrienko AA, Sides GD, Winters KG, et al. Electrocardiogram reference ranges for Lilly clinical trials. Indianapolis, Ind: Eli Lilly and Company; 2002
22. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001;12:411-420
23. Thompson WL, Brunelle RL, Enas GG, et al. Routine laboratory tests in clinical trials: 1-63. Indianapolis, Ind: Eli Lilly and Company; 1990
24. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002;63:694-699
25. De Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
26. Joffe RT, Marshall AM, Lee DK. A large open-label study of venlafaxine in depressed outpatients by community-based physicians. J Clin Psychiatry 1998;59:515-520
27. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000;20:483-487
28. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
29. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry 1999;156:829-836
30. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104
31. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003;53:754-760
32. Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993;13(6 suppl 2):28S-33S
33. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281
34. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2002
35. Prozac [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2001
36. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
37. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-161
38. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;46:42-44
39. Berger B, Stenstrom G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population: a report from the Skaraborg Diabetes Registry. Diabetes Care 1999;22:773-778
40. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care 1996;19:807-811
41. Medalie JH, Papier CM, Goldbourt U, et al. Major factors in the development of diabetes mellitus in 10.000 men. Arch Intern Med 1975;135:811-817
42. Stevens J, Ahn K, Juhaeri, et al. Dietary fiber intake and glycemic index and incidence of diabetes in African-American and white adults: the ARIC study. Diabetes Care 2002;25:1715-1721
43. Buse JB, Cavazzoni P, Hombuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-170
44. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
45. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981
46. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566